Reliéva, a Mahonia aquifolium extract for the treatment of adult patients with atopic dermatitis

Am J Ther. Sep-Oct 2007;14(5):442-6. doi: 10.1097/MJT.0b013e31814002c1.

Abstract

This clinical study was conducted to determine the efficacy and safety of Reliéva cream in adult patients with atopic dermatitis (eczema). This was an open-label trial in 42 patients with atopic dermatitis treated for 12 weeks with Reliéva cream (a homeopathic product containing Psorberine, a proprietary Mahonia aquifolium extract). Efficacy and safety was assessed using Eczema Area and Severity Index scores and a Subject Reported Evaluation of Treatment. The results showed significant (P < 0.05) improvements with respect to Eczema Area and Severity Index scores by comparison to subjects' baseline scores. In addition, subjects responding to a posttreatment evaluation questionnaire indicated a substantial benefit when rating effectiveness, itching, and appearance as a result of using the study preparation. Reliéva cream appears to be a safe and effective treatment for adult patients with atopic dermatitis (eczema).

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Aged
  • Dermatitis, Atopic / drug therapy*
  • Female
  • Humans
  • Liposomes
  • Mahonia / chemistry*
  • Male
  • Middle Aged
  • Ointments
  • Phytotherapy*
  • Plant Extracts / adverse effects
  • Plant Extracts / therapeutic use*
  • Pruritus / drug therapy
  • Pruritus / etiology
  • Severity of Illness Index

Substances

  • Liposomes
  • Ointments
  • Plant Extracts